Buy with Amazon

Friday, April 11, 2014

Sunpharma News to buy Ranbaxy labs

 Sun Pharmaceutical Industries agreed to buy Ranbaxy Laboratories limited Japan's Diiachi Sankyo, for USD 3.2 billions.that will make the new entity India's largest and the world's fifth largest drugmaker.
Ranbaxy shareholders will receive 0.8 share of Sun Pharma for each share of Ranbaxy
 Promoters of Sun Pharma will hold close to 56% while Daiichi Sankyo will hold 9% stake in the combined entity.
Daiichi Sankyo had bought Ranbaxy Laboratories for $4.6 billion in 2008.


Sun has also announced that it will reshuffle the management after the merger.

For Daiichi Sankyo the deal marks a significant retreat and highlights the lingering quality problems facing India's drug industry. 
The value of the Japanese firm's investments in the country has been halved since it bought control of Ranbaxy in 2008.
The deal comes even when Ranbaxy is facing  a slew of problems from the U.S. Food and Drug Administration (FDA) due to concerns about manufacturing processes at its India plants.
Deal is expected to be closed by end of this year. Ranbaxy will end up by holding about 9% Stake in Sun Pharma valued at about $2 billion, compared with the $4.2 billion it paid for a 63.9 % in Ranbaxy in 2008.
India is second only to Canada as a drug exporter to the U.S. 
Deal comes at 18% higher premium value of Ranbaxy Share.
In 2010 Sun Pharma bought all the outstanding shares of U.S.-based Caraco Pharmaceutical Laboratories at a time when Caraco was struggling to address manufacturing quality concerns that led to FDA bans on its plants.


Sunpharma News to buy Ranbaxy labs

 Sun Pharmaceutical Industries agreed to buy Ranbaxy Laboratories limited Japan's Diiachi Sankyo, for USD 3.2 billions.that will make the new entity India's largest and the world's fifth largest drugmaker.
Ranbaxy shareholders will receive 0.8 share of Sun Pharma for each share of Ranbaxy
 Promoters of Sun Pharma will hold close to 56% while Daiichi Sankyo will hold 9% stake in the combined entity.
Daiichi Sankyo had bought Ranbaxy Laboratories for $4.6 billion in 2008.


Sun has also announced that it will reshuffle the management after the merger.

For Daiichi Sankyo the deal marks a significant retreat and highlights the lingering quality problems facing India's drug industry. 
The value of the Japanese firm's investments in the country has been halved since it bought control of Ranbaxy in 2008.
The deal comes even when Ranbaxy is facing  a slew of problems from the U.S. Food and Drug Administration (FDA) due to concerns about manufacturing processes at its India plants.
Deal is expected to be closed by end of this year. Ranbaxy will end up by holding about 9% Stake in Sun Pharma valued at about $2 billion, compared with the $4.2 billion it paid for a 63.9 % in Ranbaxy in 2008.
India is second only to Canada as a drug exporter to the U.S. 
Deal comes at 18% higher premium value of Ranbaxy Share.
In 2010 Sun Pharma bought all the outstanding shares of U.S.-based Caraco Pharmaceutical Laboratories at a time when Caraco was struggling to address manufacturing quality concerns that led to FDA bans on its plants.